[{"id":"50824abd-5741-4674-85d5-f161af1f5d77","acronym":"","url":"https://clinicaltrials.gov/study/NCT05563545","created_at":"2022-10-03T15:56:36.271Z","updated_at":"2024-07-02T16:35:59.936Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05563545","lead_sponsor":"Shanghai Simnova Biotechnology Co.,Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • SNC103"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 11/25/2022","primary_completion_date":" 11/25/2022","study_txt":" Completion: 11/25/2022","study_completion_date":" 11/25/2022","last_update_posted":"2022-11-28"}]